drugset / Trial / NCT00501098

Prophylaxis of Fungal Invasive Infections in Leukemia

NCT00501098

Phase 2 Completed 100 enrolled Northern Italy Leukemia Group
Non-randomizedSingle-groupOpen-labelPrevention

Summary

* To assess the overall clinical yield - in terms of efficacy and safety endpoints of adding caspofungin as prophylaxis of Invasive Pulmonary Aspergillosis in patients undergoing induction treatment for newly diagnosed acute leukemia * To investigate the prognostic significance of Ptx3 at diagnosis and during the first chemotherapy cycle with respect to the development of IPA

Timeline

Start
2007-01
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Caspofungin Other / unclassified 50 mg Intravenous